Trial · NCT04230577
Registered outcomes92
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 92
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Color-Word Interference (Stroop) Test, Trial 3 _1 | Change from Pre-Treatment Baseline to 1-Week after Series 1 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 3 is a measure of Inhibition. Measures Attention/Executive Function; inhibition Measure is Reaction Time lower = better outcome Trial 3 (Inhibition): Name the color ink each word is printed in for a series of words, as quickly as possible. |
| Secondary | Color-Word Interference (Stroop) Test, Trial 3 _2 | Change from Pre-Treatment Baseline to 1-Month after Series 1 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 3 is a measure of Inhibition. Measures Attention/Executive Function; inhibition Measure is Reaction Time lower = better outcome Trial 3 (Inhibition): Name the color ink each word is printed in for a series of words, as quickly as possible. |
| Secondary | Color-Word Interference (Stroop) Test, Trial 3 _3 | Change from 1-Week to 1-Month after Series 1 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 3 is a measure of Inhibition. Measures Attention/Executive Function; inhibition Measure is Reaction Time lower = better outcome Trial 3 (Inhibition): Name the color ink each word is printed in for a series of words, as quickly as possible. |
| Secondary | Color-Word Interference (Stroop) Test, Trial 3 _4 | Change from Pre-Treatment Baseline to 1-Week after Series 2 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 3 is a measure of Inhibition. Measures Attention/Executive Function; inhibition Measure is Reaction Time lower = better outcome Trial 3 (Inhibition): Name the color ink each word is printed in for a series of words, as quickly as possible. |
| Secondary | Color-Word Interference (Stroop) Test, Trial 4 _1 | Change from Pre-Treatment Baseline to 1-Week after Series 1 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 4 is a measure of executive function: Inhibition/switching. Measures Attention/Executive Function; inhibition/switching Measure is Reaction Time lower = better outcome Trial 4 (Inhibition and Switching): Name the color of the ink, however if there is a box around the word, read the word, as quickly as possible |
| Secondary | Color-Word Interference (Stroop) Test, Trial 4 _2 | Change from Pre-Treatment Baseline to 1-Month after Series 1 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 4 is a measure of executive function: Inhibition/switching. Measures Attention/Executive Function; inhibition/switching Measure is Reaction Time lower = better outcome Trial 4 (Inhibition and Switching): Name the color of the ink, however if there is a box around the word, read the word, as quickly as possible |
| Secondary | Color-Word Interference (Stroop) Test, Trial 4 _3 | Change from 1-Week to 1-Month after Series 1 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 4 is a measure of executive function: Inhibition/switching. Measures Attention/Executive Function; inhibition/switching Measure is Reaction Time lower = better outcome Trial 4 (Inhibition and Switching): Name the color of the ink, however if there is a box around the word, read the word, as quickly as possible |
| Secondary | Color-Word Interference (Stroop) Test, Trial 4 _4 | Change from Pre-Treatment Baseline to 1-Week after Series 2 | Delis-Kaplan Executive Function (DKEFS), Color-Word Interference Test; also known as the Stroop test; Trial 4 is a measure of executive function: Inhibition/switching. Measures Attention/Executive Function; inhibition/switching Measure is Reaction Time lower = better outcome Trial 4 (Inhibition and Switching): Name the color of the ink, however if there is a box around the word, read the word, as quickly as possible |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 2) 1 | Change from Pre-Treatment Baseline to 1-Week after Series 1 | Number Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Connect the numbers in consecutive order from 1 to 16, as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 2) 2 | Change from Pre-Treatment Baseline to 1-Month after Series 1 | Number Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Connect the numbers in consecutive order from 1 to 16, as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 2) 3 | Change from 1-Week to 1-Month after Series 1 | Number Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Connect the numbers in consecutive order from 1 to 16, as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 2) 4 | Change from Pre-Treatment Baseline to 1-Week after Series 2 | Number Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Connect the numbers in consecutive order from 1 to 16, as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 4) 1 | Change from Pre-Treatment Baseline to 1-Week after Series 1 | Number and Letter Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Alternate connecting numbers and letters in consecutive order from 1 to P (1-A-2-B…) as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 4) 2 | Change from Pre-Treatment Baseline to 1-Month after Series 1 | Number and Letter Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Alternate connecting numbers and letters in consecutive order from 1 to P (1-A-2-B…) as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 4) 3 | Change from 1-Week to 1-Month after Series 1 | Number and Letter Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Alternate connecting numbers and letters in consecutive order from 1 to P (1-A-2-B…) as quickly as possible. |
| Secondary | Delis-Kaplan Executive Function Trails (Condition 4) 4 | Change from Pre-Treatment Baseline to 1-Week after Series 2 | Number and Letter Sequencing; measures Attention/Executive Function, Sequencing, Visual Scanning Measure is Reaction Time with lower = better outcome Alternate connecting numbers and letters in consecutive order from 1 to P (1-A-2-B…) as quickly as possible. |
| Secondary | Benton Visual Memory Test; Trial 1 Immediate Recall 1 | Change from Pre-Treatment Baseline to 1-Week after Series 1 | Immediate Recall for Visuospatial memory Min 0 and max 36; higher score better outcome Participant is presented with 6 figures. They are given 10 secs to view 6 pictures. Immediately asked to recall and draw the figures. Up to 2 points per figure. Scoring based on accuracy and placement of figure parts: A score of 0, 1 recognizable and incorrectly placed, 1 accurate or correctly placed or 2 both accurate and correctly placed; 0 is given if part is omitted or unrecognizable. Total possible 12 points |
| Secondary | Benton Visual Memory Test; Trial 1 Immediate Recall 2 | Change from Pre-Treatment Baseline to 1-Month after Series 1 | Immediate Recall for Visuospatial memory Min 0 and max 36; higher score better outcome Participant is presented with 6 figures. They are given 10 secs to view 6 pictures. Immediately asked to recall and draw the figures. Up to 2 points per figure. Scoring based on accuracy and placement of figure parts: A score of 0, 1 recognizable and incorrectly placed, 1 accurate or correctly placed or 2 both accurate and correctly placed; 0 is given if part is omitted or unrecognizable. Total possible 12 points |
| Secondary | Benton Visual Memory Test; Trial 1 Immediate Recall 3 | Change from 1-Week to 1-Month after Series 1 | Immediate Recall for Visuospatial memory Min 0 and max 36; higher score better outcome Participant is presented with 6 figures. They are given 10 secs to view 6 pictures. Immediately asked to recall and draw the figures. Up to 2 points per figure. Scoring based on accuracy and placement of figure parts: A score of 0, 1 recognizable and incorrectly placed, 1 accurate or correctly placed or 2 both accurate and correctly placed; 0 is given if part is omitted or unrecognizable. Total possible 12 points |
| Secondary | Benton Visual Memory Test; Trial 1 Immediate Recall 4 | Change from Pre-Treatment Baseline to 1-Week after Series 2 | Immediate Recall for Visuospatial memory Min 0 and max 36; higher score better outcome Participant is presented with 6 figures. They are given 10 secs to view 6 pictures. Immediately asked to recall and draw the figures. Up to 2 points per figure. Scoring based on accuracy and placement of figure parts: A score of 0, 1 recognizable and incorrectly placed, 1 accurate or correctly placed or 2 both accurate and correctly placed; 0 is given if part is omitted or unrecognizable. Total possible 12 points |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04230577/registered?page=2